Scott Tobin - Champions Oncology Insider
Stakeholder Scott Tobin is not found or was disassociated from the entity Champions Oncology
If you believe Scott Tobin is a valid insider of Champions Oncology please let us know and we will check it out.
Other Suggestions
| CS | Credit Suisse Group | Company |
| CSSEP | Chicken Soup for | Company |
| CSL | Carlisle Companies Incorporated | Company |
| CSQ | Calamos Strategic Total | Fund |
| CSA | VictoryShares Small Cap | ETF |
| CSPR | Casper Network | Cryptocurrency |
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Champions Stock
| 0.69 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
Moving against Champions Stock
| 0.75 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.69 | XFOR | X4 Pharmaceuticals | PairCorr |
| 0.49 | ELDN | Eledon Pharmaceuticals | PairCorr |
| 0.49 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
| 0.48 | FBRX | Forte Biosciences Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.Note that the Champions Oncology information on this page should be used as a complementary analysis to other Champions Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Champions Stock analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Champions Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Champions Oncology. If investors know Champions will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Champions Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.29) | Earnings Share (0.72) | Revenue Per Share 3.634 | Quarterly Revenue Growth (0.06) | Return On Assets (0.17) |
The market value of Champions Oncology is measured differently than its book value, which is the value of Champions that is recorded on the company's balance sheet. Investors also form their own opinion of Champions Oncology's value that differs from its market value or its book value, called intrinsic value, which is Champions Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Champions Oncology's market value can be influenced by many factors that don't directly affect Champions Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Champions Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Champions Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Champions Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.